Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451396 · ClinicalTrials.gov registry record · Phase 4
Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms
A Phase 4 study of Dry Eye, sponsored by Lifelong Vision Foundation.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03451396 is a Phase 4 study of Dry Eye that has completed, run by Lifelong Vision Foundation. The registered enrollment target is 30 participants, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03451396, a Phase 4 study of Dry Eye, has completed, sponsored by Lifelong Vision Foundation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether a fall in tear osmolarity precedes improvement in symptoms and signs of dry eye in dry eye patients treated topically with 5% lifitegrast drops for 3 months.
Conditions Studied
Interventions
- DRUG Lifitegrast
Study Locations (1)
Missouri
- Lifelong Vision Foundation - Chesterfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-12-12 |
| Est. Completion | 2018-03-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03451396
The ClinicalTrials.gov registry entry for NCT03451396 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (68% lower). The listed sponsor is Lifelong Vision Foundation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which Lifitegrast is the first listed.
NCT03451396 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03451396 about?
NCT03451396 is a clinical study titled "Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms". To determine whether a fall in tear osmolarity precedes improvement in symptoms and signs of dry eye in dry eye patients treated topically with 5% lifitegrast drops for 3 months.
What is the current status of trial NCT03451396?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2016-12-12. Estimated completion is 2018-03-15.
What conditions does trial NCT03451396 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT03451396?
The interventions under investigation include: Lifitegrast (DRUG).
Who is sponsoring clinical trial NCT03451396?
This trial is sponsored by Lifelong Vision Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03451396 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
Performance of Systane PRO Versus Refresh Optive Mega-3
RECRUITING · Phase 4
-
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.